Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

in patients with nonischemic cardiomyopathy (NICM), little is known regarding the effect of gender difference on arrhythmic risk in this population. We sought to determine if there are gender ...

Until the age of 53, Svetlana, a resident of Grodno, did not even suspect that she had a severe congenital disease — arrhythmogenic cardiomyopathy (ACM ... complex diagnostic study and established the ...

Over recent years, there have been significant strides in developing innovative anti-arrhythmic drugs ... of 4.94% during 2024-2034. Hypertrophic Cardiomyopathy Market: The 7 major hypertrophic ...

Current selection, which is based mainly on left-ventricular ejection fraction, results in a high number needed to treat (NNT) to prevent arrhythmic death (i.e ... in younger patients with myocarditis ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Over the past decades, hypertrophic cardiomyopathy has become a contemporary treatable disease. However, limited data exist on the global trends of implantable cardioverter defibrillator (ICD) ...

The term dilated cardiomyopathy (DCM) refers to a spectrum of heterogeneous myocardial disorders that are characterized by ventricular dilation and depressed myocardial performance in the absence of ...

repeat procedure (except for one redo during blanking), taking a new or previously failed class I or III anti-arrhythmic drug at higher dose after blanking, or direct current cardioversion after ...

arrhythmic triggers are not revealed; poor ECG records monitoring cannot be carried out for more than 3–4 weeks; continual maintenance is required; devices are uncomfortable; quite poor ECG ...